Bioprofarma Bagó presents CarciVac® for the treatment of non-muscle invasive bladder cancer. We are pleased to announce the launch of CarciVac® vaccine onco BCG Bacilo Calmette-Guérin. This product complements our Urology portfolio continuing our commitment to patients suffering bladder cancer.
CarciVac® is manufactured by Serum Institute of India, the world’s largest producer of vaccines, which allows us to guarantee the availability of the product in the market.
CarciVac® vaccine onco BCG Bacilo Calmette-Guérin is indicated for the treatment of:
- Flat urothelial cell carcinoma in situ (CIS) of the bladder
- As adjuvant treatment after TUR of primary or recurrent superficial papillary urothelial cell carcinoma (stage Ta and T1).
It is presented in a 40 mg lyophilized ampoule bottle for 3 vials.
For more information, please click here
